Tyrosine Kinase Inhibitor Enhances the Bioavailability of Oral Irinotecan in Pediatric Patients With Refractory Solid Tumors
AUTOR(ES)
Furman, Wayne L.
FONTE
American Society of Clinical Oncology
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2754908Documentos Relacionados
- Bioavailability of oral trimetrexate in patients with acquired immunodeficiency syndrome.
- Oral bioavailability and pharmacokinetics of ciprofloxacin in patients with AIDS.
- Oral Bioavailability and Pharmacokinetics of Trovafloxacin in Patients with AIDS
- Differences between the oral changes presented by patients with solid and hematologic tumors during the chemotherapeutic treatment
- Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Oral CP-868,596, a Highly Specific Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitor in Patients With Advanced Cancers